Predicting Outcomes in Rhabdomyosarcoma with PAX3-FKHR Gene
Author Information
Author(s): Anderson J, Gordon T, McManus A, Mapp T, Gould S, Kelsey A, McDowell H, Pinkerton R, Shipley J, Pritchard-Jones K
Primary Institution: Institute of Cancer Research, Sutton, Surrey, UK
Hypothesis
Is the PAX3-FKHR fusion gene a reliable predictor of outcome in paediatric rhabdomyosarcoma?
Conclusion
The presence of the PAX3-FKHR translocation is an adverse prognostic factor in rhabdomyosarcoma.
Supporting Evidence
- The study found that 82% of alveolar cases had one of the characteristic translocations.
- Univariate survival analysis indicated that the PAX3-FKHR translocation is an adverse prognostic factor.
- The variant PAX7-FKHR translocation occurs in younger patients with more localized disease.
Takeaway
Doctors can look for a specific gene in cancer cells to help decide how to treat kids with a type of muscle cancer.
Methodology
The study used classical cytogenetics, FISH, and RT-PCR to analyze 91 primary rhabdomyosarcoma tumors.
Limitations
The hypothesis requires testing in a prospective study.
Participant Demographics
The study included patients with varying ages and disease characteristics.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website